Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA’s Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to innovate around this...

Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to innovate around this...

In this study, we examine the effect of lenders' certification for pricing of auditing services for the borrowers. We find that loan initiation is associated with significant reduction in auditing fees. The decrease in auditing fees is more pronounced for non-syndicated loans and when the...

In response to a string of highly publicized corporate scandals, the US Congress passed the Sarbanes-Oxley Act (SOX) on July 30, 2002, with the intention to restore investors' confidence in financial and public reporting. This study addresses the question of whether any improvement in earnings...